Schering-Plough Opens State-Of-Art Lab In Singapore For Drug Efficacy
This article was originally published in PharmAsia News
Executive Summary
Schering-Plough has opened its research facility in Singapore to track the progress of drug effectiveness and allow it to focus on those most likely to succeed. The drug maker opened its new lab at the Biopolis researcher center to use the latest imaging techniques to determine biomarkers to determine whether a drug is working long before attempts are made to market it. Schering-Plough also expects the work in the new lab to determine which drugs to focus on for intended purposes as the firm concentrates on specialized medicine. (Click here for more
You may also be interested in...
EU: Good News For IVDs And For Future Transparency Of Medtech Compliance
The IVD industry has long been awaiting a further extension of the deadlines for compliance with the IVD Regulation and for the launch date of the Eudamed database to be brought forward.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.